Treating Cancer by Inhibiting Nuclear Entry of MAPK Cascade Proteins

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Inhibition of Nuclear Entry of MAPK Cascade Proteins as a Novel Mechanism for Treating Cancer


Background and Unmet Need

ERK is a major signaling molecule, which plays a driving role in various pathologies, particularly cancer. When not activated ERK is localized to the cytoplasm. Upon activation ERK binds to Importin7 (Imp7) and is translocated to the nucleus, where it elicits transcription of numerous genes related to pro-cancerous activities such as proliferation. However, anti-ERK drugs have had limited success in only certain cancer types, and development of drug resistance is a common phenomenon among patients. Anti-ERK drug resistance is usually attributed to the inhibition of the ERK-dependent negative feedback loop, which activates alternative signaling mechanisms. These mechanisms circumvent the ERK cascade, rendering the drugs ineffective.

The research group of Prof. Seger developed a peptide, which inhibits ERK without provoking the typical anti-ERK resistance mentioned above. The peptide achieves that by inhibiting the translocation of ERK to the nucleus in a manner that does not affect the negative feedback loop. This peptide has the potential to treat ERK-related diseases and cancer without inducing drug resistance, as a single therapy or in a combination with standard of care therapies. The group has also developed a small molecule that mimics the mechanism of the peptide, which holds a great promise due to its novel mechanism of action and superiority from the drugability perspective over the administration and use of peptides.

Technology Essence

The peptide interferes with the binding of ERK and Imp7 via the nuclear translocation signal (NTS). If the ERKImp7 complex is not properly assembled, ERK is not translocated to the nucleus and therefore cannot induce gene expression and further proliferation. The peptide was tested both in vitro and in vivo in various cancers (for example melanoma, breast and colon) and was shown to reduce proliferation and tumor volume.

Applications and Advantages

  • Variety of indications – can be used for many pathologies that require ERK silencing.
  • Lack of resistance – does not provoke the ERK negative feedback loop, which contributes to drug resistance.
  • Novel – inhibits ERK translocation to the nucleus rather than inhibiting general ERK function.
  • Small molecule in development to mimic peptide

Intellectual property status

  • Granted Patent
  • Patent application number :European Patent Office Published: Publication Number: 3658169 USA Granted: 9,315,547 USA Granted: 10,240,133 USA Granted: 9,695,402 USA Published: Publication Number: 2021-0292338-A1

Related Keywords

  • Biological Sciences
  • Cytology, Cancerology, Oncology
  • Protein Engineering
  • Genome Research
  • Enzymology/Protein Engineering/Fermentation
  • Medical Health related
  • Therapeutic
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support